Poland· PL-100401836
Agomelatine +pharma
A agomelatin product containing agomelatinum, registered in Poland by +pharma arzneimittel GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Agomelatin is registered in 13 of 19 countries.
Countries holding a registration under ATC N06AX22 (agomelatin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Agomelatin · ATC N06AX22
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
Price per daily dose
What a daily dose of agomelatin costs, country by country.
Normalised to the WHO defined daily dose (25 mg), the median price runs from $0.72 in France to $1.72 in Switzerland — a ×2.4 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Agomelatin · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.72
- FR France$0.72
The record
At a glance
URPL (Poland)- Active substance
- Agomelatinum
- Manufacturer
- +pharma arzneimittel GmbH
- Country
- Poland (PL)
- ATC code
- N06AX22
- ATC class
- Agomelatin
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 8
1 priced- gtin0590172014049430 szt.PLN 66.28
- gtin05901720140098
- gtin05901720140029
- gtin05901720140036
- gtin05901720140081
- gtin05901720140043
- gtin05901720140401
- gtin05901720140418
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
25 interactions on record for agomelatin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Agomelatin · interactions on record
25 records
25 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Agomelatin in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainAGLONEX 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- SwitzerlandAgomelatin Servier
- NetherlandsAgomaval 25 mg, filmomhulde tablettenKrka d.d., Novo mesto
- FranceAGOMELATINE BIOGARAN 25 mg, comprimé pelliculéBIOGARAN
- CzechiaVALDOXANLes Laboratoires Servier, Suresnes cedex
- FinlandAgomelatine AnpharmAnpharm Przedsiebiorstwo Farmaceutyczne S.A.
- SwedenAgomelatin Glenmark 25 mg Filmdragerad tablettGlenmark Arzneimittel GmbH
- IcelandAgomelatine STADASTADA Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 21 EEA countries. Names it is sold under:
- Austria · Agogerolan, Agomelatin Genericon
- Bulgaria · Агомелатин G.L. Pharma
- Czechia · Agomelatin +pharma, Agomelatine G.L.Pharma
- Germany · Agomaval, Agomelatin Abz
- Denmark · Agomelatin Glenmark, Agomelatin Stada
- Estonia · Lamegom
- Spain · Agomelatina Aurovitas Spain, Agomelatina Qualigen
- Finland · Agomelatine Stada, Agomelatine Viatris
- France · Agomelatine Biogaran, Agomelatine Eg
- United Kingdom (Northern Ireland) · Agomelatine Accord, Agomelatine Neuraxpharm
- Hungary · Agomelatin Teva, Agomelatine Anpharm
- Ireland · Agomelatine Viatris
- Iceland · Agomelatine Stada, Valdoxan
- Liechtenstein · Valdoxan
- Lithuania · Agomelatine Anpharm, Lamegom
- Malta · Agomaval
- Netherlands · Agomaval, Agomelatine Accord
- Norway · Valdoxan
- Portugal · Agomelatina Ciclum, Agomelatina Generis
- Sweden · Agomelatin Glenmark, Agomelatine Stada
- Slovakia · Agomelatín Stada, Agomelatine G.L. Pharma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b931b073-15fb-4340-abe8-d4da7ca2c1d4 GET /v1/drugs/b931b073-15fb-4340-abe8-d4da7ca2c1d4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "25 mg",
"packaging": "05901720140098 ¦ Rp ¦ 130612\n28 tabl.\n05901720140494 ¦ Rp ¦ 130613\n30 tabl.\n05901720140029 ¦ Rp ¦ Skasowane ¦ 130614\n56 tabl.\n05901720140036 ¦ Rp ¦ 130615\n60 tabl.\n05901720140081 ¦ Rp ¦ 130616\n84 tabl.\n05901720140043 ¦ Rp ¦ Skasowane ¦ 130617\n90 tabl.\n05901720140401 ¦ Rp ¦ 133871\n56 tabl.\n05901720140418 ¦ Rp ¦ 133872\n90 tabl.",
"substance": "Agomelatinum 25 mg",
"common_name": "Agomelatinum",
"pl_product_id": "100401836",
"pozwolenie_nr": "25043",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about agomelatin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.